**Traders assign a 92.5% probability to “No” on further corporate tax rate reductions before 2027 because Congress already enacted the One Big Beautiful Bill Act in July 2025.** That legislation made permanent key 2017 Tax Cuts and Jobs Act business provisions—including 100% bonus depreciation, R&D expensing, and the EBITDA-based interest limitation—while preserving the 21% corporate rate and adding targeted relief such as temporary expensing for certain manufacturing structures. No subsequent legislation or administration proposal has advanced a statutory rate cut below 21%. With legislative calendars now focused on appropriations, potential mid-term dynamics, and other priorities through 2026, the window for another major corporate rate reduction has narrowed sharply. The market price therefore reflects the absence of any concrete legislative vehicle or announced timeline for additional rate relief before the 2027 resolution date.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$15,983 Vol.
$15,983 Vol.
$15,983 Vol.
$15,983 Vol.
Note that the cut does not need to go into effect before the resolution date - it just needs to be signed into law by then.
This market's primary resolution source will be official information from the Trump administration, however a consensus of credible information will also be used.
Market Opened: Nov 5, 2025, 1:03 PM ET
Resolver
0x65070BE91...Note that the cut does not need to go into effect before the resolution date - it just needs to be signed into law by then.
This market's primary resolution source will be official information from the Trump administration, however a consensus of credible information will also be used.
Resolver
0x65070BE91...**Traders assign a 92.5% probability to “No” on further corporate tax rate reductions before 2027 because Congress already enacted the One Big Beautiful Bill Act in July 2025.** That legislation made permanent key 2017 Tax Cuts and Jobs Act business provisions—including 100% bonus depreciation, R&D expensing, and the EBITDA-based interest limitation—while preserving the 21% corporate rate and adding targeted relief such as temporary expensing for certain manufacturing structures. No subsequent legislation or administration proposal has advanced a statutory rate cut below 21%. With legislative calendars now focused on appropriations, potential mid-term dynamics, and other priorities through 2026, the window for another major corporate rate reduction has narrowed sharply. The market price therefore reflects the absence of any concrete legislative vehicle or announced timeline for additional rate relief before the 2027 resolution date.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions